Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy/chemoradiotherapy in resectable esophageal squamous cell carcinoma
NCT04974047Phase 2Completed
- Sponsor
- BeiGene
- Start
- Aug 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 cohorts), sponsored by BeiGene. Primary endpoint: Pathological Complete Response Rate. Started Aug 2021; status: completed.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04974047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974047.